Caricamento...
Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
The recently conducted ADAURA trial concludes daily dosing of adjuvant osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), improves disease-free survival with stage IB/II/IIIA EGFR -mutated non-small cell lung cancer patients in comparison to placebo. We have developed a preclinica...
Salvato in:
| Pubblicato in: | Transl Oncol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Neoplasia Press
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8236545/ https://ncbi.nlm.nih.gov/pubmed/33993094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101111 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|